SBP 101

Drug Profile

SBP 101

Alternative Names: SBP101; SUN 101

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator University of Florida
  • Developer Sun BioPharma
  • Class Antineoplastics; Polyamines
  • Mechanism of Action Apoptosis stimulants; Cell division inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer
  • Research Pancreatitis

Most Recent Events

  • 30 Mar 2017 Interim efficacy data from a phase I trial in Pancreatic cancer released by Sun BioPharma
  • 01 Feb 2017 Early research in Pancreatitis in USA (SC)
  • 01 Feb 2017 Sun Pharma receives STTR grant from the National Institute of Diabetes and Digestive and Kidney Diseases for SBP 101 development in Pancreatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top